What You Should Know:
– Dandelion Health, a real-world data (RWD) and clinical AI platform, today announced findings from a study that suggests GLP-1 medications may be effective in preventing cardiovascular disease (CVD) in a significantly larger population than previously thought.
– This research, conducted using validated AI on Dandelion’s newly launched Clinical AI Marketplace, opens the door for a new era of precision medicine and personalized care in cardiometabolic diseases.
Unveiling the Clinical AI Marketplace
Dandelion’s Clinical AI Marketplace is a revolutionary platform that empowers life sciences organizations to accelerate and optimize clinical research. By harnessing AI algorithms and robust RWD, it enables researchers to generate rapid, novel insights at a fraction of the time and cost of traditional clinical trials.
The Power of Unstructured Data
Traditional RWD is often limited to structured data, leaving a wealth of valuable information locked away in unstructured formats like imaging files, waveforms, and clinical notes. Dandelion’s Marketplace breaks down these data silos, unlocking crucial insights on treatment discontinuation, symptoms, and treatment response, enabling a deeper understanding of patient journeys.
Expanding the Reach of GLP-1s
Dandelion’s study, conducted in a mere six weeks, focused on a key question unaddressed in clinical trials: Can GLP-1s be used as a primary prevention tool for heart attacks and strokes in individuals without pre-existing severe cardiovascular disease?
Leveraging AI biomarkers and its GLP-1 data library, Dandelion examined a far broader population than those studied in clinical trials. Findings suggest that GLP-1s may result in a 15%–20% lower risk of major adverse cardiovascular events (MACE) in this previously unstudied group, potentially benefiting 44 million additional patients.
AI: Accelerating Clinical Research and Improving Patient Care
Dandelion’s approach demonstrates how AI can de-risk and expedite clinical research, enabling life sciences companies to make informed decisions on clinical trials, treatment comparisons, and market access. Additionally, these insights empower providers to make personalized treatment choices, leading to earlier interventions and better patient outcomes.
“The combined power of real-world data and AI has the potential to reshape how life sciences conduct clinical trials and research,” said Shivaani Prakash, MSc, PhD, Head of Data at Dandelion Health. “By combining diverse, multimodal data with validated AI, life sciences companies and researchers can now study treatment effects on a far larger, more representative population — and do so at a fraction of the cost and time.”
